RxDoctor Payments Data

Pablo Robles Cortes, MD

Internal Medicine · Lajas, PRNPI 1225188816

Payments from drug & device makers

$3,744in general payments, 2019–2025

Across 70 payments — averaging $53.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • AstraZeneca$841
  • PBG Puerto Rico LLC$108
  • Sanofi-aventis U.S. LLC$78
  • GSK$76
  • Sanofi$43
  • plus $112 from 4 others

What the payments were for

  • Consulting fees$2,45065%
  • Food & beverage$1,28834%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck8$2,485
AstraZeneca44$841
PBG Puerto Rico LLC6$108
Sanofi-aventis U.S. LLC4$78
GSK2$76
Sanofi1$43
Hikma Pharmaceuticals USA2$39
Johnson & Johnson1$39
Biohaven Pharmaceutical Holding Company Ltd.1$19
Pfizer Pharmaceuticals LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,744 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,985
Medicare patients
19
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol199$134,904
JanumetSitagliptin Phos/Metformin Hcl168$122,596
JentaduetoLinagliptin/Metformin Hcl144$88,068
EliquisApixaban122$77,657
XareltoRivaroxaban124$74,555
BrilintaTicagrelor86$34,732
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm304$32,397
JanuviaSitagliptin Phosphate42$26,208
LantusInsulin Glargine,hum.Rec.Anlog213$23,797
SynthroidLevothyroxine Sodium292$19,956
Xigduo XrDapaglifloz Propaned/Metformin30$18,549
JardianceEmpagliflozin22$17,197
LumiganBimatoprost52$14,266
Losartan Potassium1,707$14,253
Gabapentin2,167$14,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$841$169,635285 claims
MerckJanumet, Januvia$2,485$148,804210 claims
Johnson & JohnsonXarelto$39$74,555124 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$78$34,658225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Lajas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →